603079.SHG Zhejiang Shengda Pharm
- Market cap
- CNY 2.19B
- P/E
- 60.9x
- P/B
- 1.32x
- ROE
- 2.1%
- Dividend yield
- 0.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603079.SHG undervalued?
Graham number603079.SHG trades 89.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Shengda Pharm fundamental analysis
No fundamental analysis for Zhejiang Shengda Pharm yet.
Zhejiang Shengda Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. engages in the developing, producing, and selling of food and feed additives in China and internationally. The company offers vitamins, such as biotin and folic acid; biopreservatives and functional ingredients, including nisin, natamycin, polylysine, and sucrose fermentation products; and intermediate APIs. It serves pharmaceutical, nutritional, food, and animal feed industries. The company was incorporated in 1999 and is headquartered i…
Full company profileZhejiang Shengda Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Shengda Pharm annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 482M | 509M | 493M | 519M | 867M | 790M | 738M | 727M | 827M | 845M | 791M |
| Gross Profit | 171M | 191M | 157M | 174M | 455M | 216M | 110M | 74.2M | 164M | 221M | 212M |
| Operating Income | 63.1M | 85.8M | 52.3M | 50.7M | 247M | 81.4M | 36.1M | -45.7M | 46.6M | 84.5M | 75.4M |
| EBITDA | 104M | 129M | 91.9M | 112M | 298M | 157M | 109M | 28.6M | 125M | 158M | 67.1M |
| Net Income | 60.9M | 72.6M | 44.5M | 47.0M | 197M | 75.8M | 31.5M | -54.1M | 29.4M | 62.2M | 33.5M |
| EPS | 0.52 | 0.56 | 0.29 | 0.30 | 1.17 | 0.44 | 0.18 | -0.32 | 0.17 | 0.33 | 0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 741M | 986M | 1.25B | 1.53B | 1.70B | 1.76B | 1.66B | 1.72B | 1.79B | 2.20B | 2.28B |
| Total Liabilities | 301M | 217M | 424M | 621M | 376M | 428M | 312M | 449M | 501M | 584M | 659M |
| Shareholders' Equity | 440M | 769M | 791M | 884M | 1.30B | 1.32B | 1.33B | 1.25B | 1.26B | 1.58B | 1.58B |
| Cash & Short-term Investments | 176M | 295M | 316M | 327M | 461M | 515M | 321M | 327M | 316M | 458M | 524M |
| Total Debt | 92.5M | 60.0M | 137M | 350M | 115M | 157M | 33.5M | 238M | 262M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 73.0M | 95.3M | 88.7M | 58.6M | 333M | 74.5M | 40.7M | 64.4M | 148M | 139M | - |
| Capital Expenditure | 53.8M | 46.9M | 145M | 186M | 85.2M | 100.0M | 63.3M | 246M | 170M | 146M | 121M |
| Free Cash Flow | 19.2M | 48.5M | -55.8M | -127M | 248M | -25.5M | -22.5M | -182M | -22.0M | -6.80M | -36.1M |
| Ratios | |||||||||||
| ROE | 13.8% | 9.4% | 5.6% | 5.3% | 15.1% | 5.7% | 2.4% | -4.3% | 2.3% | 3.9% | 2.1% |
| ROA | 8.2% | 7.4% | 3.6% | 3.1% | 11.6% | 4.3% | 1.9% | -3.1% | 1.6% | 2.8% | 1.5% |
| Net Profit Margin | 12.6% | 14.3% | 9.0% | 9.1% | 22.8% | 9.6% | 4.3% | -7.4% | 3.6% | 7.4% | 4.2% |
| Debt to Equity | 0.21x | 0.08x | 0.17x | 0.40x | 0.09x | 0.12x | 0.03x | 0.19x | 0.21x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Shengda Pharm dividends
- Dividend yield
- 0.36%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 12.6%
- Ex-dividend date
- Jul 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 7.81M | 0.04 | 12.6% |
| 2024 | CNY 18.1M | 0.10 | 61.4% |
| 2023 | CNY 10.3M | 0.06 | - |
| 2022 | CNY 24.0M | 0.14 | 76.1% |
| 2021 | CNY 59.9M | 0.35 | 79.1% |
| 2020 | CNY 14.7M | 0.09 | 7.4% |
| 2019 | CNY 13.4M | 0.09 | 28.6% |
| 2018 | CNY 26.5M | 0.17 | 59.4% |
| 2017 | CNY 65.0M | 0.50 | 89.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 8, 2020.
Who owns Zhejiang Shengda Pharm
- Insiders 52.52%
- Institutions 2.49%
- Public & others 44.99%
- Shares outstanding 189M
- Free float 100M
Zhejiang Shengda Pharm company profile
- Company name
- Zhejiang Shengda Pharm
- Ticker
- 603079.SHG
- ISIN
- CNE100002W43
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,083
- Fiscal year end
- December
- Address
- No. 18 , Shifeng East Road, Tiantai, China, 317200
- Phone
- 86 576 8388 1111
- Website
- sd-pharm.com
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. engages in the developing, producing, and selling of food and feed additives in China and internationally. The company offers vitamins, such as biotin and folic acid; biopreservatives and functional ingredients, including nisin, natamycin, polylysine, and sucrose fermentation products; and intermediate APIs. It serves pharmaceutical, nutritional, food, and animal feed industries. The company was incorporated in 1999 and is headquartered in Tiantai, China.
Zhejiang Shengda Pharm management
5- Ms. Chao LiangGM & Head of Accounting · born 1988
- Mr. Xiang Xiao XuActing Board Secretary, CFO & Accounting Supervisor · born 1980
- Ms. Jing ZhuDeputy General Manager · born 1986
- Mr. Xiao XieDeputy General Manager · born 1986
- Ms. Chaoqun HongDeputy General Manager · born 1987